<DOC>
	<DOCNO>NCT01530386</DOCNO>
	<brief_summary>The effect Lacosamide , antiepileptic drug , sleep formally evaluate . The present study conduct assess effect Lacosamide sleep quality healthy subject .</brief_summary>
	<brief_title>A Multicenter , Open-label Study Determine Effects Lacosamide Sleep Healthy Subjects</brief_title>
	<detailed_description>In patient Epilepsy , seizure activity associate specific phase sleep/wake cycle , sleep deprivation know precipitate seizure activity . Inadequate disturb sleep excessive daytime drowsiness often report patient Epilepsy due effect seizures well antiepileptic drug . Thus , use healthy subject improve certainty change sleep related study drug factor .</detailed_description>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Reliable capable subject sign IRB approve consent form Subject male female 18 50 year old whose normal Body Mass Index ( BMI ) 18 28 kg/m^2 Subject clinically relevant cardiovascular , renal , gastrointestinal , hepatic , metabolic , endocrine , neurological psychiatric abnormality Subject good health good sleep hygiene normal bed time 21:00 01:00 hour Subjects participate previous Lacosamide study receive Lacosamide Subjects receive another investigational medication within 30 day currently participate investigational study Subject history screen polysomnography reveals sleep disorder ( i.e . sleep apnea narcolepsy ) Subject consume 400 mg caffeine per day Subject know hypersensitivity Lacosamide Subject alcohol drug abuse within last 2 year Subject consume 40 g alcohol per day Subject positive alcohol breath test urine drug screen Subject smoke half pack cigarette per day consumes nicotine product Subject pregnant / nursing childbearing potential female sterile use contraception method Subject male agree use contraception Subjects take medication currently within 2 week prior first dose except nonsteroidal antiinflammatory drug , oral contraceptive , nonpsychoactive supplement Subject elevate live enzyme great 2 time upper limit normal Subject donate blood blood loss great 400 mL within 3 month prior first dose Subject range hematology chemistry parameter Subject clinically relevant abnormality physical examination vital sign Subject sick sinus syndrome without pace maker second third degree atrioventricular block clinically significant electrocardiogram find Subject sodium channelopathy Subject experience myocardial infarction last 3 month Subject New York Heart Association Class III IV heart failure Subject lifetime history suicide attempt Subject medical psychiatric condition Subject know history severe anaphylactic reaction serious blood dyscrasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Lacosamide</keyword>
	<keyword>Vimpat</keyword>
</DOC>